2025 Q4 -tulosraportti
32 päivää sitten
‧32 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 12 500 | - | - | ||
| 2 050 | - | - | ||
| 750 | - | - | ||
| 2 200 | - | - | ||
| 25 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 819 383 | 819 383 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 819 383 | 819 383 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·6 t sittenCB states what he thinks about the KDIGO situation. Now you have it straight from the horse's mouth. I must frankly admit that I am glad that what I have found out aligns with what CB states below. The upcoming updates to the KDIGO guidelines, which are moving towards biomarker-based diagnostics and prevention, constitute a potential structural tailwind for BioPorto's NGAL test, as this can accelerate adoption in clinical practice. https://www.inderes.dk/analyst-comments/bioporto-budskaber-fra-hca-investor-seminar-16-april-2026?utm_source=nordnet&utm_medium=integration·3 t sittenBioPorto price target 2026: Analysts see 71% upside https://tradedesk.dk/stock/biopor.co- ·1 päivä sittenI have been thinking about how it can be that when KDIGO comes up with a grade 1, everyone in the industry, within the recommended area, follows their recommendation. This is where Paul Palevsky comes into the picture, because if he is part of a grade 1 recommendation, then everyone apparently knows that he only does so if the KDIGO committee has calculated that the topic will save the treatment facility money when they use the topic as a fixed procedure in their treatments of the sick. Therefore, the affected areas, worldwide, at once, will have integrated the NGAL test. In the USA, there is also another reason why hospitals follow the recommendation; they will do so to avoid a lawsuit from relatives if one of their patients dies after this recommendation and they did not have the NGAL test as a fixed part of their treatments. So therefore, the question will not be whether they follow the recommendation, because they will. The question must be, does Bioporto have enough kits for the enormous demand that will come at once? I maintain that there will be two recommendations for the NGAL test. Anything else would be illogical.·7 t sittenyes, I have googled a lot, after I found out that KDIGO's decision is very important for Bioporto, which I have also written previously, that I have surfed around the internet to get as much information as possible. That information is for those who have an interest in knowing what KDIGO is and why it is so important for Bioporto,, and what recommendations I expect them to receive, based on what I find out. So I haven't made anyone believe that it all came to me out of the blue. As I wrote, it is for those who have an interest in the above, so don't read the upcoming posts, it sounds like it's not for you.
- ·3 päivää sittenIt has just been announced on KDIGO's website that the hearing has been extended until May 11. Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) https://kdigo.org/guidelines/acute-kidney-injury/
·2 päivää sitten3D writes "It is not unusual, and we cannot read anything into it, and whether it is a good or less good recommendation that is coming." I completely agree with that assessment. If only 3D could stick to the first assessment. The custom believes there must be both interpretation and reading between the lines, in something that "cannot be read into", if the first statement is correct, and without it coming as a surprise to anyone, 3D naturally finds a positive angle and forgets the OBJECTIVE angle. - ·3 päivää sittenProceedings of the ordinary general meeting https://www.globenewswire.com/news-release/2026/04/24/3280911/0/en/resolutions-of-the-annual-general-meeting.html
·3 päivää sittenNext week it will go over 1 kr and stay there, as there must be some momentum😁·2 päivää sittenInteresting Born. You must have been busy with a very thorough analysis on this lovely and windy day.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
32 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6 t sittenCB states what he thinks about the KDIGO situation. Now you have it straight from the horse's mouth. I must frankly admit that I am glad that what I have found out aligns with what CB states below. The upcoming updates to the KDIGO guidelines, which are moving towards biomarker-based diagnostics and prevention, constitute a potential structural tailwind for BioPorto's NGAL test, as this can accelerate adoption in clinical practice. https://www.inderes.dk/analyst-comments/bioporto-budskaber-fra-hca-investor-seminar-16-april-2026?utm_source=nordnet&utm_medium=integration·3 t sittenBioPorto price target 2026: Analysts see 71% upside https://tradedesk.dk/stock/biopor.co
- ·1 päivä sittenI have been thinking about how it can be that when KDIGO comes up with a grade 1, everyone in the industry, within the recommended area, follows their recommendation. This is where Paul Palevsky comes into the picture, because if he is part of a grade 1 recommendation, then everyone apparently knows that he only does so if the KDIGO committee has calculated that the topic will save the treatment facility money when they use the topic as a fixed procedure in their treatments of the sick. Therefore, the affected areas, worldwide, at once, will have integrated the NGAL test. In the USA, there is also another reason why hospitals follow the recommendation; they will do so to avoid a lawsuit from relatives if one of their patients dies after this recommendation and they did not have the NGAL test as a fixed part of their treatments. So therefore, the question will not be whether they follow the recommendation, because they will. The question must be, does Bioporto have enough kits for the enormous demand that will come at once? I maintain that there will be two recommendations for the NGAL test. Anything else would be illogical.·7 t sittenyes, I have googled a lot, after I found out that KDIGO's decision is very important for Bioporto, which I have also written previously, that I have surfed around the internet to get as much information as possible. That information is for those who have an interest in knowing what KDIGO is and why it is so important for Bioporto,, and what recommendations I expect them to receive, based on what I find out. So I haven't made anyone believe that it all came to me out of the blue. As I wrote, it is for those who have an interest in the above, so don't read the upcoming posts, it sounds like it's not for you.
- ·3 päivää sittenIt has just been announced on KDIGO's website that the hearing has been extended until May 11. Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) https://kdigo.org/guidelines/acute-kidney-injury/·2 päivää sitten3D writes "It is not unusual, and we cannot read anything into it, and whether it is a good or less good recommendation that is coming." I completely agree with that assessment. If only 3D could stick to the first assessment. The custom believes there must be both interpretation and reading between the lines, in something that "cannot be read into", if the first statement is correct, and without it coming as a surprise to anyone, 3D naturally finds a positive angle and forgets the OBJECTIVE angle.
- ·3 päivää sittenProceedings of the ordinary general meeting https://www.globenewswire.com/news-release/2026/04/24/3280911/0/en/resolutions-of-the-annual-general-meeting.html
- ·3 päivää sittenNext week it will go over 1 kr and stay there, as there must be some momentum😁·2 päivää sittenInteresting Born. You must have been busy with a very thorough analysis on this lovely and windy day.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 12 500 | - | - | ||
| 2 050 | - | - | ||
| 750 | - | - | ||
| 2 200 | - | - | ||
| 25 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 819 383 | 819 383 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 819 383 | 819 383 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
2025 Q4 -tulosraportti
32 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6 t sittenCB states what he thinks about the KDIGO situation. Now you have it straight from the horse's mouth. I must frankly admit that I am glad that what I have found out aligns with what CB states below. The upcoming updates to the KDIGO guidelines, which are moving towards biomarker-based diagnostics and prevention, constitute a potential structural tailwind for BioPorto's NGAL test, as this can accelerate adoption in clinical practice. https://www.inderes.dk/analyst-comments/bioporto-budskaber-fra-hca-investor-seminar-16-april-2026?utm_source=nordnet&utm_medium=integration·3 t sittenBioPorto price target 2026: Analysts see 71% upside https://tradedesk.dk/stock/biopor.co
- ·1 päivä sittenI have been thinking about how it can be that when KDIGO comes up with a grade 1, everyone in the industry, within the recommended area, follows their recommendation. This is where Paul Palevsky comes into the picture, because if he is part of a grade 1 recommendation, then everyone apparently knows that he only does so if the KDIGO committee has calculated that the topic will save the treatment facility money when they use the topic as a fixed procedure in their treatments of the sick. Therefore, the affected areas, worldwide, at once, will have integrated the NGAL test. In the USA, there is also another reason why hospitals follow the recommendation; they will do so to avoid a lawsuit from relatives if one of their patients dies after this recommendation and they did not have the NGAL test as a fixed part of their treatments. So therefore, the question will not be whether they follow the recommendation, because they will. The question must be, does Bioporto have enough kits for the enormous demand that will come at once? I maintain that there will be two recommendations for the NGAL test. Anything else would be illogical.·7 t sittenyes, I have googled a lot, after I found out that KDIGO's decision is very important for Bioporto, which I have also written previously, that I have surfed around the internet to get as much information as possible. That information is for those who have an interest in knowing what KDIGO is and why it is so important for Bioporto,, and what recommendations I expect them to receive, based on what I find out. So I haven't made anyone believe that it all came to me out of the blue. As I wrote, it is for those who have an interest in the above, so don't read the upcoming posts, it sounds like it's not for you.
- ·3 päivää sittenIt has just been announced on KDIGO's website that the hearing has been extended until May 11. Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) https://kdigo.org/guidelines/acute-kidney-injury/·2 päivää sitten3D writes "It is not unusual, and we cannot read anything into it, and whether it is a good or less good recommendation that is coming." I completely agree with that assessment. If only 3D could stick to the first assessment. The custom believes there must be both interpretation and reading between the lines, in something that "cannot be read into", if the first statement is correct, and without it coming as a surprise to anyone, 3D naturally finds a positive angle and forgets the OBJECTIVE angle.
- ·3 päivää sittenProceedings of the ordinary general meeting https://www.globenewswire.com/news-release/2026/04/24/3280911/0/en/resolutions-of-the-annual-general-meeting.html
- ·3 päivää sittenNext week it will go over 1 kr and stay there, as there must be some momentum😁·2 päivää sittenInteresting Born. You must have been busy with a very thorough analysis on this lovely and windy day.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 12 500 | - | - | ||
| 2 050 | - | - | ||
| 750 | - | - | ||
| 2 200 | - | - | ||
| 25 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 819 383 | 819 383 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 819 383 | 819 383 | 0 | 0 |